Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404397 | 0.87 | PYGL (0.63) | PYGL | |
| SCHEMBL14404226 | 0.84 | PYGL (0.65) | PYGL | |
| SCHEMBL14404590 | 0.81 | PYGL (0.44) | PYGL | |
| SCHEMBL5631059 | 0.79 | PYGL (1.00) | PYGL | |
| SCHEMBL7561781 | 0.75 | PYGL (0.61) | PYGL | |
| SCHEMBL5629495 | 0.75 | PYGL (0.85) | PYGL | |
| SCHEMBL14404227 | 0.73 | PYGL (0.65) | PYGL | |
| SCHEMBL4797202 | 0.72 | PYGL (0.55) | PYGL | |
| SCHEMBL4797181 | 0.72 | PYGL (0.55) | PYGL | |
| SCHEMBL5642750 | 0.72 | PYGL (0.82) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | PYGL, PYGM, GYS1 | PYGL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.